Follow
Subscribe to Helmholtz Munich

Helmholtz Munich

Filter
  • 05.06.2023 – 17:16

    Unraveling the Mode of Action of Tirzepatide

    Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the contribution of activating the GIP receptor in the overall efficacy of ...

  • 22.05.2023 – 17:26

    Diagnosis of Type 1 Diabetes After SARS-CoV-2 Infection: Researchers Find Possible Correlation

    During the COVID-19 pandemic, an increase in the chronic autoimmune disease type 1 diabetes was observed in children, also in Germany. Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern (KVB), have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the ...

  • 15.05.2023 – 16:48

    Ambient ultrafine particles – very small and very dangerous?

    A new study conducted by Helmholtz Munich researchers reveals that ultrafine particles, representing the smallest size fraction of particulate air pollution, might be more dangerous to human health than larger particles. These findings add to the growing body of evidence that it may be insufficient to focus on larger particle concentrations and gases when assessing public health risks. It was now published in the ...